Precigenetics
Precigenetics is revolutionizing drug discovery by providing real-time epigenetic insights for precision medicine and targeted therapies. Its proprietary COMPASS platform offers non-destructive, single-cell analysis of epigenetic changes, accelerating discovery timelines and enabling high-throughput applications. The company focuses on precision oncology, empowering researchers and clinicians to address diseases accurately with immediate biological feedback, thereby eliminating guesswork in treatment response.
Precigenetics
Precigenetics is revolutionizing drug discovery by providing real-time epigenetic insights for precision medicine and targeted therapies. Its proprietary COMPASS platform offers non-destructive, single-cell analysis of epigenetic changes, accelerating discovery timelines and enabling high-throughput applications. The company focuses on precision oncology, empowering researchers and clinicians to address diseases accurately with immediate biological feedback, thereby eliminating guesswork in treatment response.
TL;DR
Stage: Pre-seed / early stage
Headquarters: Philadelphia, Pennsylvania, United States
Core product: COMPASS — real-time, non-destructive single-cell epigenetic analysis platform
Founder / CEO: Parmita Mishra
Known investors: 1517 Fund; O'Shaughnessy Ventures
Company Overview
Problem Domain
Precision medicine and targeted therapies, with a focus on precision oncology and accelerating drug discovery via single-cell epigenetic analysis.
Founded
2024
Industry
Biotechnology
Tech Stack
Funding Track Record
Investors reported: 1517 Fund; O'Shaughnessy Ventures
Investor Signal
“1517 Fund; O'Shaughnessy Ventures”